Albert Bourla, CEO of Pfizer, discusses the company's strategic focus on innovative medicine, the rapid development of the COVID-19 vaccine, and the acquisition of Metsera to enter the obesity market. He also highlights the rise of Chinese biotech companies, which operate with significantly lower costs and higher speed, and emphasizes the urgent need for transformation through AI and technology to stay competitive.
Summarized by Podsumo
Pfizer's entry into the obesity market via the Metsera acquisition aims to capitalize on a monthly product, potentially differentiating from weekly competitors like Novo Nordisk.
Chinese biotech firms are now operating at 'half the cost and three times the speed,' with eight of the top ten universities in scientific output being Chinese, according to the Nature Index.
Albert Bourla stresses that a five-year transformation through AI and technology is critical for Pfizer to compete with the rising efficiency of Chinese companies.
The CEO notes that Pfizer's R&D, commercial, and manufacturing strengths were undermined by a scientific setback—liver toxicity in two promising obesity assets—leading to the Metsera deal.
"I'm always excited by the future... science is at the highest levels we ever had it."